Chemical Synthesis of Monomeric, Dimeric and Tetrameric Forms of the Ectodomain of Influenza Matrix 2 Protein

The highly conserved ectodomain of M2 protein (M2e) of influenza virus A is one of the most studied vaccine targets for induction of cross-strain protection. It has been reported that the native form of M2 is a homo-tetramer linked by disulfide bonds and that antibodies reactive to this form correlate with M2-mediated protection. Although vaccine constructs mimicking the quaternary structure of M2 have been described, the chemical syntheses of disulfide-linked dimeric and tetrameric forms of M2e have not yet been reported. By exploiting orthogonal chemistry during the syntheses, we successfully assembled dimeric and tetrameric forms of M2e but found that the antibodies that they elicited had protection properties similar to those of the monomeric form. There was, therefore no advantage mimicking the native conformation to improve vaccine efficacy. Nevertheless, the synthetic strategies have the potential for use in preparation of other dimeric or tetrameric constructs.

[1]  D. Jackson,et al.  A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate. , 2015, Vaccine.

[2]  D. Jackson,et al.  A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli. , 2012, Vaccine.

[3]  J. Katz,et al.  Development and evaluation of an M2-293FT cell-based flow cytometric assay for quantification of antibody response to native form of matrix protein 2 of influenza A viruses. , 2011, Journal of immunological methods.

[4]  W. Zeng,et al.  A Modular Approach to Assembly of Totally Synthetic Self-adjuvanting Lipopeptide-based Vaccines Allows Conformational Epitope Building* , 2011, The Journal of Biological Chemistry.

[5]  R. Compans,et al.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus , 2010, Proceedings of the National Academy of Sciences.

[6]  S. Epstein,et al.  Cross-protective immunity to influenza A viruses , 2010, Expert review of vaccines.

[7]  S. Rockman,et al.  A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody , 2010, Immunology and cell biology.

[8]  W. Fiers,et al.  M2e-based universal influenza A vaccine. , 2009, Vaccine.

[9]  W. Fiers,et al.  Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments , 2009, Expert review of vaccines.

[10]  J. Shiver,et al.  Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. , 2009, Virology.

[11]  J. Shiver,et al.  Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. , 2009, Vaccine.

[12]  J. Wade,et al.  Synthesis, Conformation, and Activity of Human Insulin-Like Peptide 5 (INSL5) , 2008, Chembiochem : a European journal of chemical biology.

[13]  W. Fiers,et al.  An Influenza A Vaccine Based on Tetrameric Ectodomain of Matrix Protein 2* , 2008, Journal of Biological Chemistry.

[14]  Ying-hua Chen,et al.  Characterization of immunity induced by M2e of influenza virus. , 2007, Vaccine.

[15]  L. Otvos,et al.  Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse , 2007, Virology Journal.

[16]  J. Wade,et al.  Improved chemical synthesis and demonstration of the relaxin receptor binding affinity and biological activity of mouse relaxin. , 2007, Biochemistry.

[17]  Barbara Imperiali,et al.  Protein oligomerization: how and why. , 2005, Bioorganic & medicinal chemistry.

[18]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[19]  W. Fiers,et al.  A "universal" human influenza A vaccine. , 2004, Virus research.

[20]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[21]  L. Otvos,et al.  Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. , 2003, Vaccine.

[22]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[23]  R. Lamb,et al.  The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Hay,et al.  Structural characteristics of the M2 protein of influenza a viruses: Evidence that it forms a tetrameric channe , 1991, Virology.

[25]  V. Nussenzweig,et al.  Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria , 1990, The Journal of experimental medicine.

[26]  R. Lamb,et al.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface , 1985, Cell.

[27]  R. Lamb,et al.  Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. , 1981, Virology.

[28]  W. Kowalczyk,et al.  Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study. , 2010, Bioconjugate chemistry.